Idiopathic Pulmonary Fibrosis Market Report 2026

The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $4.37 billion in 2025 to $4.66 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to limited treatment options for fibrotic lung diseases, rising prevalence of aging population, improved clinical recognition of IPF, approval of nintedanib and pirfenidone, increased hospital-based management of chronic lung disorders.

The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $6.16 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing research investment in pulmonary fibrosis, development of next-generation antifibrotic drugs, increasing use of real-world evidence in treatment decisions, expansion of online and specialty pharmacy channels, rising awareness of rare respiratory diseases. Major trends in the forecast period include increasing adoption of antifibrotic therapies, rising focus on early and accurate diagnosis, growing use of combination drug therapies, expansion of home-based and long-term disease management, increasing participation in clinical trials for novel therapies.

The increasing geriatric population is expected to drive growth in the idiopathic pulmonary fibrosis (IPF) market in the coming years. The geriatric population, consisting of elderly or senior individuals, is more susceptible to respiratory diseases due to age-related structural and functional changes in the lungs. This vulnerability contributes to greater demand for IPF treatments. For example, in January 2024, the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. During this period, their share of the total US population is expected to grow from 17% to 23%. Therefore, the expanding geriatric population is supporting the growth of the IPF market.

Key companies in the IPF market are focusing on innovative therapies, such as anti-fibrotic small-molecule inhibitors, to maintain a competitive edge. Anti-fibrotic small-molecule inhibitors are pharmaceutical compounds designed to target and inhibit fibrotic processes in the body. For instance, in June 2023, Insilico Medicine, a US-based clinical-stage biotechnology company using generative artificial intelligence (AI), initiated Phase II clinical trials for INS018_055, the world’s first anti-fibrotic small-molecule inhibitor designed using generative AI. The trial, a randomized, double-blind, placebo-controlled study, evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of a 12-week oral dosage of INS018_055 in subjects with IPF. This approach highlights the potential of AI-driven drug discovery in advancing IPF treatment.

In October 2023, Aileron Therapeutics, a US-based biopharmaceutical company, acquired Lung Therapeutics Inc. for an undisclosed amount. This acquisition strengthens Aileron’s therapeutic pipeline by adding the clinical-stage IPF asset LTI-03, accelerating development in idiopathic pulmonary fibrosis. Lung Therapeutics, also based in the US, focuses on developing novel peptide-based therapies, including LTI-03, a Caveolin-1-related peptide for orphan pulmonary fibrosis indications such as IPF.

Major companies operating in the idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

North America was the largest region in the idiopathic pulmonary fibrosis market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the idiopathic pulmonary fibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the idiopathic pulmonary fibrosis market by increasing costs for imported active pharmaceutical ingredients, drug formulations, and manufacturing equipment used in antifibrotic therapies. These effects are more evident in regions dependent on cross-border pharmaceutical supply chains, including parts of Asia-Pacific and Latin America. At the same time, tariffs are encouraging localized drug manufacturing, supply chain diversification, and strategic partnerships, which may enhance long-term treatment availability and market resilience.

The idiopathic pulmonary fibrosis market research report is one of a series of new reports that provides idiopathic pulmonary fibrosis market statistics, including idiopathic pulmonary fibrosis industry global market size, regional shares, competitors with a idiopathic pulmonary fibrosis market share, detailed idiopathic pulmonary fibrosis market segments, market trends and opportunities, and any further data you may need to thrive in the idiopathic pulmonary fibrosis industry. This idiopathic pulmonary fibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by the gradual deterioration of the tissue surrounding the air sacs (alveoli) in the lungs. This leads to the formation of scar tissue (fibrosis), which impairs the efficient transfer of oxygen into the bloodstream.

The main drug types used in IPF treatment include nintedanib, pirfenidone, and other therapies. Nintedanib is prescribed for conditions such as IPF, progressive interstitial lung disease, and interstitial lung disease associated with systemic sclerosis. The primary mechanisms of action include antifibrotic activity, tyrosine kinase inhibition, and others. These drugs are administered via oral or parenteral routes. Key distribution channels include hospital pharmacies, retail pharmacies, and online platforms, serving end-users such as hospitals, clinics, and other healthcare facilities.

The idiopathic pulmonary fibrosis (IPF) market consists of sales of anti-inflammatory, MAPK inhibitors, autotoxin inhibitors and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.